Literature DB >> 18585842

Is maintenance Bacillus Calmette-Guérin really necessary?

Harry W Herr.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18585842     DOI： 10.1016/j.eururo.2008.06.062

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


× No keyword cloud information.
  15 in total

Review 1.  [Urothelial carcinoma].

Authors:  H Rübben; F Vom Dorp
Journal:  Urologe A       Date:  2011-09       Impact factor: 0.639

2.  Is it possible to stop follow-up of patients with primary T1G3 urothelial carcinoma of the bladder managed with intravesical bacille Calmette-Guérin immunotherapy?

Authors:  Thomasz Golabek; Joan Palou; Oscar Rodríguez; Josep Maria Gaya; Alberto Breda; Humberto Villavicencio
Journal:  World J Urol       Date:  2016-06-09       Impact factor: 4.226

Review 3.  Intravesical therapy for urothelial carcinoma of the urinary bladder: a critical review.

Authors:  Daher C Chade; Shahrokh F Shariat; Guido Dalbagni
Journal:  Int Braz J Urol       Date:  2009 Nov-Dec       Impact factor: 1.541

Review 4.  Landmarks in non-muscle-invasive bladder cancer.

Authors:  Laura S Mertens; Yann Neuzillet; Simon Horenblas; Bas W G van Rhijn
Journal:  Nat Rev Urol       Date:  2014-07-01       Impact factor: 14.432

5.  Single monthly bacillus Calmette-Guérin intravesical instillation is effective maintenance therapy to prevent recurrence in Japanese patients with non-muscle-invasive bladder cancer.

Authors:  Takehiko Okamura; Hidetoshi Akita; Ryosuke Ando; Yosuke Ikegami; Taku Naiki; Noriyasu Kawai; Keiichi Tozawa; Kenjiro Kohri
Journal:  Int J Clin Oncol       Date:  2011-09-28       Impact factor: 3.402

Review 6.  [Intravesical therapy of non-muscle invasive bladder tumors].

Authors:  F Vom Dorp; S Tschirdewahn; G Lümmen
Journal:  Urologe A       Date:  2012-02       Impact factor: 0.639

Review 7.  [Non-muscle-invasive transitional cell carcinoma. Is BCG still a necessary part of treatment?].

Authors:  F vom Dorp; S Tschirdewahn; H Rübben; D Jocham
Journal:  Urologe A       Date:  2010-10       Impact factor: 0.639

8.  The application of adjuvant autologous antravesical macrophage cell therapy vs. BCG in non-muscle invasive bladder cancer: a multicenter, randomized trial.

Authors:  Maximilian Burger; Nicolas Thiounn; Stefan Denzinger; Jozsef Kondas; Gerard Benoit; Manuel S Chapado; Fernando J Jimenz-Cruz; Laszlo Kisbenedek; Zoltán Szabo; Domján Zsolt; Marc O Grimm; Imre Romics; Joachim W Thüroff; Tamas Kiss; Bertrand Tombal; Manfred Wirth; Marc Munsell; Bonnie Mills; Tung Koh; Jeff Sherman
Journal:  J Transl Med       Date:  2010-06-08       Impact factor: 5.531

9.  Prognostic role of substaging in T1G3 transitional cell carcinoma of the urinary bladder.

Authors:  Vincenzo DE Marco; Maria Angela Cerruto; Carolina D'Elia; Matteo Brunelli; Oscar Otte; Anila Minja; Claudio Luchini; Giovanni Novella; Stefano Cavalleri; Guido Martignoni; Walter Artibani
Journal:  Mol Clin Oncol       Date:  2014-05-08

Review 10.  [Intravesical therapy in non-muscle-invasive bladder cancer: indications and practical considerations].

Authors:  J Simon; F Finter; T Schnöller; R Hautmann; L Rinnab
Journal:  Urologe A       Date:  2009-11       Impact factor: 0.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.